Life Sciences weekly highlights—20 February 2025
This week's edition of Life Sciences weekly highlights includes news analysis of the European Commission’s withdrawal of the AI Liability Directive withdrawal as part of last week’s 2025 Work Programme. Also included, is news that NICE announced proposals to transform its HealthTech programme, the European medical devices industry published a joint reflection paper calling for the EU to become a full member of the Medical Device Single Audit Program, NICE has teamed up with the US and Canada to establish the Health Economics Methods Advisory (HEMA) international initiative to evaluate health technology assessment (HTA) methods and the British pharmaceutical industry remains concerned about the ‘at or below’ principle in NHS England’s updated commercial framework for new medicines that include indication-specific pricing as an alternative to uniform pricing and sharing data for combination therapies. Other stories included are that the EMA has initiated the development of a new guideline on the assessment and reporting of mechanistic models used in model-informed drug development, the EMA published a revised draft reflection paper outlining non-animal replacement tests for pharmaceutical testing and updated its guidance on biosimilar medicines; among other stories.